Communications on Unapproved Use of Approved Products is Focus of Draft Guidance

The FDA has issued a draft guidance intended to strike a balance between health care providers’ interest in scientific information on unapproved uses of approved/cleared medical products and mitigating the FDA’s interest in prohibiting use of a product for an unapproved indication.
Source: Drug Industry Daily